A combination therapy with BRAF (dabrafenib) and MEK inhibitors (trametinib) showed a significantly longer progression-free survival, a higher number of patients who were alive and progression-free at 1 year, and higher tumor regression in patients with metastatic melanoma and BRAFV600E mutation [9]. Here, MAP2K7 is linked to neoplasm.